Bicara Therapeutics Inc. $BCAX Shares Purchased by Braidwell LP

Key Points

• Braidwell LP increased its stake in Bicara Therapeutics Inc. by 8.1%, owning approximately 3.97% of the company, valued at $28.2 million as of the latest SEC filing.
• Equities analysts have mixed ratings for Bicara Therapeutics, with price targets ranging from $8.00 to $41.00 and an average price target of $32.25.
• Bicara Therapeutics reported an earnings per share of ($0.50) for the last quarter, exceeding analysts' expectations of ($0.54).

Braidwell LP increased its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 8.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,162,803 shares of the company's stock after purchasing an additional 162,144 shares during the period. Braidwell LP owned 3.97% of Bicara Therapeutics worth $28,181,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Millennium Management LLC grew its stake in Bicara Therapeutics by 28.7% in the 4th quarter. Millennium Management LLC now owns 385,406 shares of the company's stock worth $6,714,000 after acquiring an additional 85,847 shares during the period. Northern Trust Corp purchased a new stake in Bicara Therapeutics in the 4th quarter worth approximately $2,771,000. Deutsche Bank AG purchased a new stake in Bicara Therapeutics in the 4th quarter worth approximately $1,959,000. Bank of America Corp DE grew its stake in Bicara Therapeutics by 278.4% in the 4th quarter. Bank of America Corp DE now owns 33,677 shares of the company's stock worth $587,000 after acquiring an additional 24,777 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Bicara Therapeutics by 27.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 29,138 shares of the company's stock worth $508,000 after acquiring an additional 6,279 shares during the period.

Bicara Therapeutics Trading Up 0.5%

NASDAQ BCAX traded up $0.06 during trading hours on Thursday, reaching $12.06. The company's stock had a trading volume of 199,254 shares, compared to its average volume of 581,552. The business has a 50-day simple moving average of $10.87 and a 200 day simple moving average of $11.85. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $28.09. The stock has a market cap of $658.03 million and a PE ratio of -3.80.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.04. As a group, equities analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. HC Wainwright lowered their target price on shares of Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, August 22nd. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective for the company in a research note on Friday, May 23rd. Piper Sandler initiated coverage on shares of Bicara Therapeutics in a research note on Monday, August 18th. They set an "overweight" rating and a $36.00 price objective for the company. Wall Street Zen cut shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Wedbush reissued an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Bicara Therapeutics presently has an average rating of "Buy" and a consensus price target of $32.25.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.